ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?"
Episode Synopsis
Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
More episodes of the podcast GRACEcast Bladder Cancer Video
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31/07/2014
Management of Rare Kidney Tumors
29/07/2014
NanoString Treatment for Kidney Cancer
24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
What is PD1 and PDL1 in Kidney Cancer?
15/07/2014
In God we trust